Table 1.
Oncology product approvals reporting neuro-oncology outcomes in product labeling between January 1, 2020 and December 31, 2020
| Oncology product | Approval date | Approval type | Indication | Neuro-oncology relevance |
|---|---|---|---|---|
| Selumetinib | 4/10/2020 | Regular | Neurofibromatosis Type 1 | Plexiform neurofibromas |
| Tucatinib | 4/17/2020 | Regular | HER2 + breast cancer | Brain metastases |
| Selpercatinib | 5/8/2020 | Accelerated | RET fusion + NSCLC | Brain metastases |
| Brigatinib | 5/22/2020 | Regular | ALK + NSCLC | Brain metastases |
| Pralsetinib | 9/4/2020 | Accelerated | RET fusion + NSCLC | Brain metastases |
HER2 + human epidermal growth factor receptor 2-positive, RET rearranged during transfection, NSCLC non-small cell lung cancer, ALK anaplastic lymphoma kinase